Sage Therapeutics (NASDAQ:SAGE) Institutional Investors Sentiment Index Improved in 2019 Q1

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Sentiment for Sage Therapeutics (NASDAQ:SAGE)

Sage Therapeutics (NASDAQ:SAGE) institutional sentiment increased to 1.95 in 2019 Q1. Its up 0.88, from 1.07 in 2018Q4. The ratio has improved, as 144 investment professionals opened new and increased stock positions, while 74 sold and reduced positions in Sage Therapeutics. The investment professionals in our partner’s database now have: 53.89 million shares, up from 47.40 million shares in 2018Q4. Also, the number of investment professionals holding Sage Therapeutics in their top 10 stock positions increased from 3 to 5 for an increase of 2. Sold All: 27 Reduced: 47 Increased: 96 New Position: 48.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $9.72 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

The stock increased 0.18% or $0.34 during the last trading session, reaching $189.96. About 472,627 shares traded or 15.06% up from the average. Sage Therapeutics, Inc. (NASDAQ:SAGE) has declined 2.09% since July 14, 2018 and is downtrending. It has underperformed by 6.52% the S&P500.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on August, 6. They expect $-3.32 EPS, down 822.22 % or $2.96 from last year’s $-0.36 per share. After $-3.37 actual EPS reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -1.48 % EPS growth.

Dafna Capital Management Llc holds 8.49% of its portfolio in Sage Therapeutics, Inc. for 123,806 shares. Bb Biotech Ag owns 1.38 million shares or 5.5% of their US portfolio. Moreover, Eventide Asset Management Llc has 4.41% invested in the company for 805,000 shares. The New York-based Ghost Tree Capital Llc has invested 3.23% in the stock. Hood River Capital Management Llc, a Oregon-based fund reported 350,368 shares.

Since January 1, 0001, it had 0 insider purchases, and 2 insider sales for $4.45 million activity.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Ratings analysis reveals 100% of SAGE Therapeutics’s analysts are positive. Out of 9 Wall Street analysts rating SAGE Therapeutics, 9 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $170 while the high is $249. The stock’s average target of $212.67 is 11.96% above today’s ($189.96) share price. SAGE was included in 14 notes of analysts from February 19, 2019. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Piper Jaffray on Tuesday, February 19. The firm has “Buy” rating given on Wednesday, March 20 by Piper Jaffray. The stock has “Buy” rating by Cowen & Co on Tuesday, February 19. Morgan Stanley maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Monday, February 25. Morgan Stanley has “Buy” rating and $215 target. The company was maintained on Wednesday, March 20 by Stifel Nicolaus. Ladenburg maintained the stock with “Buy” rating in Wednesday, March 20 report. As per Wednesday, March 20, the company rating was maintained by Cowen & Co. The rating was maintained by RBC Capital Markets with “Buy” on Wednesday, February 20. SunTrust maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Wednesday, March 20 with “Buy” rating. The firm has “Buy” rating given on Tuesday, February 19 by Oppenheimer.

More notable recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: Nasdaq.com which released: “Discover Financial’s Payment Brand Ties Up With Sage Pay – Nasdaq” on May 29, 2019, also Nasdaq.com with their article: “Discover Financial Inks Deal for Merchant Acceptance in Spain – Nasdaq” published on June 14, 2019, Finance.Yahoo.com published: “Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy? – Yahoo Finance” on June 19, 2019. More interesting news about Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: Nasdaq.com and their article: “XBI, MRTX, SAGE, PTLA: Large Inflows Detected at ETF – Nasdaq” published on February 19, 2019 as well as Businesswire.com‘s news article titled: “Sage Therapeutics to Host “Sage FutureCast” Webcast – Business Wire” with publication date: June 27, 2019.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.